Mylan recalls 15 lots of blood pressure drug in US

Mylan will recall at least 15 lots of medications containing valsartan in the U.S. after the drug was found to contain a cancer-causing impurity, according to Reuters. This is the latest recall of valsartan amid heightened safety concerns about the drug.

The company's decision to recall the batches comes one day after European regulators banned sales of valsartan after the impurity, N-nitrosodiethylamine was discovered.

Over the last year, several other drugmakers, including Major Pharmaceuticals, Solco Healthcare and Teva Pharmaceuticals, have recalled valsartan products under heightened scrutiny from regulators.

Read the full report here.

More articles on pharmacy:
5 recent pharma layoffs
Novartis has spent $15B to reinvent itself
AstraZeneca starts search for new CEO under pressure from stakeholders

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers